血清N端B型脑钠肽前体水平与急性冠脉综合征患者行急诊PCI院内发生心力衰竭的关系被引量：1

下载PDF

导出

摘要目的:观察血清N端B型脑钠肽前体(NT-proBNP)水平与急性冠脉综合征患者行急诊经皮冠状动脉介入治疗(PCI)院内发生心力衰竭的关系。方法:收治急性冠脉综合征患者124例,发生心力衰竭的作为研究组,未发生心力衰竭的作为对照组。比较两组患者的NT-proBNP水平、左心室射血分数(LVEF),统计不同纽约心脏病协会心功能(NYHA)分级心衰患者的NT-proBNP、LVEF水平。结果:研究组LVEF低于对照组,NT-proBNP高于对照组(P<0.05);不同NYHA分级NT-proBNP、LVEF水平差异有统计学意义(P<0.05)。结论:血清N端B型脑钠肽前体水平是反映急性冠脉综合征患者行急诊PCI院内发生心力衰竭的重要指标。

作者陈锐

机构地区广西柳州市人民医院急诊科

出处《中国社区医师》 2019年第11期115-115,117,共2页 Chinese Community Doctors

基金课题名称:院前急救心力衰竭患者血浆BNP与心电图QRS波时限及Tp-Te间期的相关性研究合同编号:Z2015117

关键词急性冠脉综合征经皮冠状动脉介入治疗 B型脑钠肽前体心力衰竭

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献5

1急性冠脉综合征急诊快速诊疗指南[J].中华急诊医学杂志,2016,25(4):397-404. 被引量：556
2王喆.《中国心力衰竭诊断和治疗指南2014》解读[J].中国临床医生杂志,2016,44(5):14-16. 被引量：239
3韩大兴,王芳芳,周宇廷,李宇周,公小纪,张宁.慢性心力衰竭患者血清肌钙蛋白Ⅰ脑钠肽与纽约心脏病协会心功能分级及心脏超声参数相关性分析[J].山西医药杂志,2017,46(9):1022-1024. 被引量：63
4陈文哲,邱春光.急性冠脉综合征患者抗血小板治疗研究进展[J].中国循证心血管医学杂志,2016,8(2):240-242. 被引量：16
5芦照青,王国兴,刘凤奎.急性心力衰竭患者NT-proBNP水平、影响因素及其与容量负荷和预后的相关性研究[J].临床和实验医学杂志,2017,16(2):163-166. 被引量：49

二级参考文献82

1Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. BMJ,2002,324(7329):71-86.
2Steg PG,Huber K,Andreotti F,et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology[J]. Eur Heart J,2011,32(15): 1854-64.
3Sherwood MW,Morrow DA,Scirica BM,et al. Early dynamic riskstratification with baseline troponin levels and 90-minute ST- segment resolution to predict 30-day cardiovascular mortality in ST- segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28[J]. Am Heart J,2010,159(6):964-71.
4Mehta SR,Yusuf S,Peters RJ,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet,2001,358(9281):527-33.
5Windecker S,Kolh P,Alfonso F,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Enr Heart J,2014,35(37):2541-619.
6Cannon CP,I-Iarrington RA,James S,et al. Comparison of ticagrelor with elopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study[J]. Lancet,2010,375(9711):283-93.
7Kang HJ,Clare RM,Gao R,et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial[J]. Am Heart J,2015,169(6):899-905.
8Stephanwindecker,Kolh P,Alfonso F,et al. 2014 ESC/EACTS guidelines on myocardial revascularization[J]. Rev Esp Cardiol (Engl Ed),2015,68(2):144.
9Becker RC,Bassand JP,Budaj A,et al. Bleeding complications with the "P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial[J]. Eur Heart J,2011,32(23):2933-44.
10Mathews R,Wang TY,Honeycutt E,et al. Persistence with secondaIy prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study[J]. Am Heart J,2015,170(1):62-9.